Response to Comment on Russell et al. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care 2023;46:1005-1013.
作者信息
Russell William E, Moore Daniel J, Herold Kevan C
机构信息
Departments of Pediatrics and Cell & Developmental Biology, Vanderbilt University Medical Center, Nashville, TN.
Departments of Pediatrics and Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN.
出版信息
Diabetes Care. 2023 Nov 1;46(11):e210-e211. doi: 10.2337/dci23-0050.
Abstract
摘要
相似文献
1
Response to Comment on Russell et al. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care 2023;46:1005-1013.对关于罗素等人的评论的回应。阿巴西普延缓1型糖尿病高危一级亲属疾病进展：一项随机、双盲、对照试验。《糖尿病护理》2023年；46:1005 - 1013。
Diabetes Care. 2023 Nov 1;46(11):e210-e211. doi: 10.2337/dci23-0050.
2
Comment on Russell et al. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care 2023;46:1005-1013.评论罗素等人的研究。阿巴西普延缓1型糖尿病进展在1期高危亲属中的应用：一项随机、双盲、对照试验。《糖尿病护理》2023年；46:1005 - 1013。
Diabetes Care. 2023 Nov 1;46(11):e209. doi: 10.2337/dc23-1115.
3
Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial.阿巴西普治疗 1 型糖尿病高危 1 期患者的进展：一项随机、双盲、对照试验。
Diabetes Care. 2023 May 1;46(5):1005-1013. doi: 10.2337/dc22-2200.
4
Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.阿巴西普治疗近期发病 1 型糖尿病患者的共刺激调节作用：一项随机、双盲、安慰剂对照试验。
Lancet. 2011 Jul 30;378(9789):412-9. doi: 10.1016/S0140-6736(11)60886-6. Epub 2011 Jun 28.
5
B lymphocyte alterations accompany abatacept resistance in new-onset type 1 diabetes.B 淋巴细胞改变伴随依那西普治疗新发 1 型糖尿病的耐药。
JCI Insight. 2019 Feb 21;4(4). doi: 10.1172/jci.insight.126136.
6
In patients at high risk for RA, abatacept reduced inflammation and RA development at 6 mo.在有发生类风湿关节炎风险的患者中，阿巴西普在 6 个月时可减轻炎症和类风湿关节炎的发生。
Ann Intern Med. 2024 Jul;177(7):JC79. doi: 10.7326/ANNALS-24-00740-JC. Epub 2024 Jul 2.
7
Comment on Haidar et al. A Randomized Crossover Trial to Compare Automated Insulin Delivery (the Artificial Pancreas) With Carbohydrate Counting or Simplified Qualitative Meal-Size Estimation in Type 1 Diabetes. Diabetes Care 2023;46:1372-1378.对海达尔等人的评论。一项随机交叉试验，比较1型糖尿病患者中自动胰岛素输注（人工胰腺）与碳水化合物计数或简化的定性餐量估计。《糖尿病护理》2023年；46:1372 - 1378。
Diabetes Care. 2023 Oct 1;46(10):e207-e208. doi: 10.2337/dc23-1243.
8
Response to Comment on Russell-Jones et al. Diabetes Care 2017;40:943-950. Comment on Bowering et al. Diabetes Care 2017;40:951-957.对关于拉塞尔 - 琼斯等人的评论的回应。《糖尿病护理》2017年；40:943 - 950。对鲍林等人的评论。《糖尿病护理》2017年；40:951 - 957。
Diabetes Care. 2018 Mar;41(3):e29-e30. doi: 10.2337/dci17-0051.
9
CTLA-4 Ig as an effective treatment in a patient with type I diabetes mellitus and seropositive rheumatoid arthritis.CTLA-4 Ig作为1型糖尿病合并血清学阳性类风湿关节炎患者的一种有效治疗方法。
Clin Exp Rheumatol. 2016 Mar-Apr;34(2):315-7. Epub 2015 Nov 17.
10
Comment on Russell-Jones et al. Diabetes Care 2017;40:943-950. Comment on Bowering et al. Diabetes Care 2017;40:951-957.对拉塞尔 - 琼斯等人的评论。《糖尿病护理》2017年；40:943 - 950。对鲍林等人的评论。《糖尿病护理》2017年；40:951 - 957。
Diabetes Care. 2018 Mar;41(3):e27-e28. doi: 10.2337/dc17-1916.
引用本文的文献
1
The Frequency but not the Phenotype of Circulating Peripheral T Helper Cells is Increased at Later Stages of Progression to Type 1 Diabetes.在进展为1型糖尿病的后期阶段，循环外周辅助性T细胞的频率增加，但表型未改变。
Eur J Immunol. 2025 Jun;55(6):e51704. doi: 10.1002/eji.202451704.
2
Comparison of immunological and immunogenetic markers in recent-onset type 1 diabetes among children and adults.儿童和成人近期发病的1型糖尿病免疫和免疫遗传标志物的比较。
Sci Rep. 2025 May 3;15(1):15491. doi: 10.1038/s41598-025-99664-8.
3
Immunotherapy-Based Strategies for Treatment of Type 1 Diabetes.基于免疫疗法的1型糖尿病治疗策略
Horm Res Paediatr. 2024 Oct 14:1-10. doi: 10.1159/000542002.
本文引用的文献
1
Comment on Russell et al. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care 2023;46:1005-1013.评论罗素等人的研究。阿巴西普延缓1型糖尿病进展在1期高危亲属中的应用：一项随机、双盲、对照试验。《糖尿病护理》2023年；46:1005 - 1013。
Diabetes Care. 2023 Nov 1;46(11):e209. doi: 10.2337/dc23-1115.
2
Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.伊马替尼治疗近期发病 1 型糖尿病患者的多中心、随机、双盲、安慰剂对照 2 期临床试验。
Lancet Diabetes Endocrinol. 2021 Aug;9(8):502-514. doi: 10.1016/S2213-8587(21)00139-X. Epub 2021 Jun 29.
3
Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial.抗白细胞介素-21 抗体和利拉鲁肽对近期诊断 1 型糖尿病成人患者β细胞功能的保护作用：一项随机、双盲、安慰剂对照、2 期临床试验。
Lancet Diabetes Endocrinol. 2021 Apr;9(4):212-224. doi: 10.1016/S2213-8587(21)00019-X. Epub 2021 Mar 1.
4
Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus.硫唑嘌呤和泼尼松用于近期发病的胰岛素依赖型糖尿病的免疫抑制治疗
N Engl J Med. 1988 Sep 8;319(10):599-604. doi: 10.1056/NEJM198809083191002.
5
Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial.环孢素可提高近期发病的胰岛素依赖型糖尿病的缓解率并延长缓解期。一项多中心双盲试验的结果。
Lancet. 1986 Jul 19;2(8499):119-24. doi: 10.1016/s0140-6736(86)91943-4.
Zotero 插件